Compare AbCellera Biologics Inc (ABCL) vs Zscaler Inc (ZS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Zscaler Inc — how do they compare? AbCellera Biologics Inc trades at $7.11 (market cap $2.35B), while Zscaler Inc trades at $143.6 (market cap $24.18B). The key difference: Zscaler Inc is far larger — about 10.3× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Zscaler Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | ZS | |
|---|---|---|
Market Cap | $2.35B | $24.18B |
Sector | Health | Technology |
52-Week High | $8.12 | $336.27 |
52-Week Low | $2.78 | $118.05 |
Enterprise Value | $1.99B | $22.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Zscaler (ZS) trades at $149.50, up 1.47% with strong technical momentum and bullish moving average signals. The company shows impressive revenue growth from $1.1B in 2022 to $2.67B in 2025, though remains unprofitable with a -2.44% net margin. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $1.08 surpassing the $1.01 forecast. Technical indicators show the stock trading near pivot point resistance at $149 with support at $145.
ZS presents a growth investment case with 79% analyst buy ratings and $192.64 consensus target, offering 29% upside. However, profitability challenges, ongoing class action investigations, and projected negative 2026 cash flow pose significant risks. The stock's high valuation multiples (P/S 7.53, EV/EBITDA 157.24) require sustained growth execution to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
